PAPPA, pappalysin 1, 5069

N. diseases: 125; N. variants: 12
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation
0.090 AlteredExpression phenotype BEFREE The findings suggest a possible pathophysiological link between the development of FGR and the expression of PAPPA, PAPPA2 and PLAC-1. 29532882 2018
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation
0.090 Biomarker phenotype BEFREE Associations with mean arterial pressure (MAP), mean uterine artery pulsatility index (UtA-PI), pregnancy-associated plasma protein A (PAPP-A), placental growth factor (PlGF), and risks for PE < 34 weeks, PE < 37 weeks and FGR < 37 weeks were analyzed using correlation analysis and univariable and multivariable linear regressions. 29318732 2018
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation
0.090 Biomarker phenotype BEFREE The area under receiver operating characteristic (ROC) curve of PAPP-A was lower than that of PROK1 and PROK1/PAPP-A in differentiating PE and FGR from the uncomplicated group (p < .001). 28675948 2018
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation
0.090 Biomarker phenotype BEFREE In the presence of a RAT, pregnancy-associated plasma protein-A is predictive of placental dysfunction and fetal growth restriction. 29956348 2018
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation
0.090 Biomarker phenotype BEFREE This study aimed to determine whether pregnancy-associated plasma protein-A (PAPP-A), free β-human chorionic gonadotropin (β-hCG), a disintegrin and metalloprotease 12 (ADAM12), and placenta protein 13 (PP13) in the first trimester, and uterine artery Doppler (UAD) in the second trimester, predict preeclampsia and fetal growth restriction (FGR). 28600048 2017
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation
0.090 AlteredExpression phenotype BEFREE The aim of the present study was to determine a predictive model for early-onset preeclampsia with fetal growth restriction (FGR) to be used at 11<sup>+0</sup> to 13<sup>+6</sup> gestational weeks, by combining the maternal serum level of pregnancy-associated plasma protein-A (PAPP-A), placental growth factor (PLGF), placental protein 13 (PP13), soluble endoglin (sEng), mean arterial pressure (MAP), and uterine artery Doppler. 27678097 2017
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation
0.090 GeneticVariation phenotype BEFREE Pregnancy-associated plasma protein A gene polymorphism in pregnant women with preeclampsia and intrauterine growth restriction. 26520690 2015
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation
0.090 GeneticVariation phenotype BEFREE Nevertheless, a combination of low PAPP-A and interpretation of chromosomal mosaicism might identify pregnancies at particular risk for fetal growth restriction. 22505498 2012
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation
0.090 Biomarker phenotype BEFREE Patients with ICP had increased serum levels of PAPP-A compared to controls and correlation analysis showed significant relationship between PAPP-A and CRP (C-reactive protein) in the patients with intrauterine growth restriction (r=0.49, p=0.007). 21986593 2011